Aerpio pharma Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

Listing Results Aerpio pharma Contact Number

Aerpio Pharmaceuticals Crunchbase Company Profile & …

9 hours ago Crunchbase.com Show details

(513) 985-1924Legal Name Aerpio Therapeutics, Inc. Stock Symbol NASDAQ:ARPO. Company Type For Profit. Phone Number (513) 985-1924. Aerpio Pharmaceuticals is a …

Founded: 2011
Founder: Dr Joseph Gardner

Category: Contact NumberShow more

ARPO Stock Aerpio Pharmaceuticals, Inc. SEC Filings

Just Now Sec.report Show details

Aerpio Pharmaceuticals Inc is a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases. The company's product AKB-9778, is a Tie2 activator being developed for the treatment of diabetic eye disease. Other products under the pipeline are cc-1536 and c-4924. Company Details.

Fiscal Year End: 12-31
State of Incorporation: DELAWARE
Reporting File Number: 001-38560

Category: Contact NumberShow more

SEC Filing Aadi Bioscience, Inc. ir.aerpio.com

6 hours ago Ir.aerpio.com Show details

On March 5, 2021, Aerpio Pharmaceuticals, Inc. issued a press release titled “Quantum Leap Healthcare Collaborative Discontinues Testing of Aerpio Pharmaceutical’s Razuprotafib in I-SPY COVID Trial.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated into this Item 8.01 by reference.

Category: Contact NumberShow more

SEC Filing Aadi Bioscience, Inc. Aerpio

6 hours ago Ir.aerpio.com Show details

Commission File Number 000-53057 . Aerpio Pharmaceuticals, Inc. (Exact name of Registrant as specified in its Charter)

Category: Contact NumberShow more

Whitfield v Aerpio Pharmaceuticals, Inc et al 1:21CV

4 hours ago Unicourt.com Show details

Docket (#1) COMPLAINT against Aerpio Pharmaceuticals, Inc., Caley Castelein, Cheryl Cohen, Anupam Dalal, Pravin Dugel, Joseph Gardner, Steve Prelack. (Filing Fee $ 402.00, Receipt Number ANYSDC-24758177)Document filed by Matthew Whitfield.. (Serra, Gina) (Entered: 07/06/2021)

Category: Contact NumberShow more

SEC FORM D

4 hours ago Sec.gov Show details

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number. * This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996

Category: Contact NumberShow more

Contingent Value Rights Agreement dated August 26, 2021

7 hours ago Contracts.justia.com Show details

Contingent Value Rights Agreement dated August 26, 2021, by and between Aerpio Pharmaceuticals, Inc., Cheryl Cohen, as Holder Representative, and American Stock Transfer & Trust Company, LLC, as Rights Agent from Aerpio Pharmaceuticals, Inc. filed with the Securities and Exchange Commission.

Category: Contact NumberShow more

Weir v. Aerpio Pharmaceuticals, Inc. et al, 1:21cv06456

6 hours ago Docketalarm.com Show details

Aerpio Pharmaceuticals, Inc. et al, 1:21-cv-06456, No. 1 (S.D.N.Y. Jul. 29, 2021) Case 1:21-cv-06456 Document 1 Filed 07/29/21 Page 1 of 14. `. `IN THE UNITED STATES DISTRICT COURT. `FOR THE SOUTHERN DISTRICT OF NEW YORK.

Category: Contact NumberShow more

Aerpio Pharmaceuticals, Inc. Investigation Weiss Law LLP

9 hours ago Weisslaw.co Show details

Aerpio Pharmaceuticals, Inc. Investigation. We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Aerpio Pharmaceuticals, Inc. (“Aerpio” or the “Company”) (NASDAQ: ARPO) in connection with the proposed merger of the Company with privately-held Aadi Bioscience, Inc. (“Aadi”).

Category: Contact NumberShow more

Carlisle v. Aerpio Pharmaceuticals, Inc. et al, 1:21cv

1 hours ago Docketalarm.com Show details

`Case 1:21-cv-01123-UNA Document 1 Filed 08/02/21 Page 2 of 12 PageID #: 2 ` `2. ` `On May 17, 2021, Aerpio and Aadi jointly announced their entry into an Agreement

Category: Contact NumberShow more

PREM14A sec.gov

1 hours ago Sec.gov Show details

125-21-1941This information is available to you without charge on the SEC’s website (www.sec.gov). Aerpio stockholders will also be able to obtain the proxy statement, free of charge, from Aerpio by requesting copies in writing using the following contact information: Aerpio Pharmaceuticals, Inc. Attn: Secretary . 9987 Carver Road . Cincinnati, OH 45242

Category: Contact NumberShow more

Aerpio Pharmaceuticals Inc (ARPO) Up 46.78% in Premarket

3 hours ago Investorsobserver.com Show details

Aerpio Pharmaceuticals Inc (Aerpio Pharmaceuticals Inc is higher by Thursday morning, with the stock increasing 46.78% in pre-market trading to 2.51.ARPO's short-term technical score of 53 indicates that the stock has traded more bullishly over the last month than 53% of stocks on the market.

Category: Contact NumberShow more

Aerpio Therapeutics VentureRadar

Just Now Ventureradar.com Show details

Aerpio is a leader in the development of small molecule drugs based on Tie2 activation and the stabilization of hypoxia-inducible factor 1α (HIF1α). The Company's lead program, AKB9778, is a firstinclass stabilizer of the Tie2 pathway and is in clinical development for diabetic macular edema." Show more Show less.

Category: Contact NumberShow more

Aerpio Pharmaceuticals Funding, Financials, Valuation

8 hours ago Crunchbase.com Show details

Aerpio Pharmaceuticals has raised a total of $107.5M in funding over 6 rounds. Their latest funding was raised on Mar 16, 2017 from a Venture - Series Unknown round. Aerpio Pharmaceuticals is registered under the ticker NASDAQ:ARPO . Aerpio Pharmaceuticals is funded by 11 investors.

Category: Contact NumberShow more

AERPIO PHARMACEUTICALS : ARPO Stock Price US00810B1052

5 hours ago Marketscreener.com Show details

Aerpio Pharmaceuticals et Aadi Bioscience vont fusionner pour former une société cotée .. 2021: Quantum Leap Healthcare abandonne les essais du Razuprotafib d'Aerpio Pharmaceutical da.. 2021: Aerpio Pharma entame une revue stratégique pour augmenter la valeur pour les actionnair..

Category: Contact NumberShow more

Arpo Overview, News & Competitors ZoomInfo.com

1 hours ago Zoominfo.com Show details

Aerpio Pharmaceuticals (ARPO) is a biopharmaceutical company focused on developing compounds that activate Tie2. Tie2 is considered a key regulator of vascular stability, and ARPO “believes that activation of Tie2 may have therapeutic potential” for different indications.

Category: Contact NumberShow more

How to buy Aerpio Pharmaceuticals stock 27 May price $1.7

8 hours ago Finder.com Show details

Aerpio Pharmaceuticals stocks (ARPO.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.76 – an increase of 0.59% over the previous week. Aerpio Pharmaceuticals employs 12 staff and has a market cap (total outstanding stock value) of $104.9 million.

Category: Contact NumberShow more

Buy Aerpio Pharmaceuticals Inc Stock ARPO Stock Price

Just Now Public.com Show details

Aadi Bioscience, Inc. operates as a clinical-stage biopharmaceutical company. It develops precision therapies for genetically-defined cancers patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes. The company was founded by Neil Desai in October, 2011 and is headquartered in Los Angeles, CA.

Category: Contact NumberShow more

Aerpio Therapeutics – Montrose Capital Partners

8 hours ago Montrosecapital.com Show details

Aerpio Therapeutics: Is a biopharmaceutical company focused on the development of novel therapeutics for vascular disorders with a concentration on diseases of the eye. The lead programs include a Tie2 activator for diabetic retinopathy (DR) and a hypoxia-inducible factor α (HIF-α) stabilizer for the treatment of inflammatory bowel disease.

Category: Contact NumberShow more

Penny Stock Aerpio Pharmaceuticals’ Merger With Aadi Makes

7 hours ago Finance.yahoo.com Show details

Aerpio’s operating expenses increased 36.7% year-over-year to $5.6 million in Q1. The company had cas Aerpio Pharmaceuticals (ARPO) is a biopharmaceutical company focused on developing compounds

Category: Contact NumberShow more

Aerpio Pharmaceuticals, Inc. (ARPO) 10K Annual Reports

6 hours ago Last10k.com Show details

The Company expects to report top-line data from the enrolled patients during the second quarter of 2021. The following information was filed by Aerpio Pharmaceuticals, Inc. (ARPO) on Thursday, March 11, 2021 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition.

Category: Contact NumberShow more

AERPIO PHARMACEUTICALS, INC. : Submission of Matters to a

7 hours ago Marketscreener.com Show details

Item 5.07. Submission of Matters to a Vote of Security Holders. On August 17, 2021, Aerpio Pharmaceuticals, Inc. (the "Company") held a Special Meeting of Stockholders (the "Special Meeting") in a virtual-only format via live webcast. Proxies were solicited pursuant to the Company's Definitive Proxy Statement filed on July 8, 2021 with the Securities and …

Category: Contact NumberShow more

Aerpio Pharmaceuticals, Inc. (ARPO) Upgraded to Strong Buy

6 hours ago Finance.yahoo.com Show details

Earnings Estimate Revisions for Aerpio Pharmaceuticals, Inc. For the fiscal year ending December 2020, this company is expected to earn -$0.36 per share, which is a change of 32.1% from the year

Category: Contact NumberShow more

AERPIO ALERT: Bragar Eagel & Squire, P.C. Investigates

1 hours ago Ca.finance.yahoo.com Show details

(646) 860-9157If you own shares of Aerpio and are concerned about the proposed merger, or you are interested in learning more about the investigation or your legal rights and remedies, please contact Melissa Fortunato or Alexandra Raymond by email at [email protected] or telephone at (646) 860-9157, or by filling out this contact form.

Category: Contact NumberShow more

Aerie Pharmaceuticals Leading Ophthalmic Pharmaceuticals

4 hours ago Aeriepharma.com Show details

aerie. We discover, develop, and commercialize first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases, and retinal diseases. Inspiration. Imagination. Innovation. We have a passion for finding new ways to protect vision. With unique scientific and technical expertise, deep clinical insight and a

Category: Contact NumberShow more

Aerpio Company Profile: Acquisition & Investors PitchBook

7 hours ago Pitchbook.com Show details

Aerpio Pharmaceuticals Inc is a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases. The company's product razuprotafib is a small molecule Tie2 activator being developed for the topical ocular treatment of primary open-angle glaucoma. Other products under the pipeline are ARP-1536 and AKB-4924.

Category: Contact NumberShow more

Aerpio Pharmaceuticals 2021 Investment ARPO 27.59 0

9 hours ago Macroaxis.com Show details

Aerpio Pharmaceuticals is currently unavailable and cannot be used in your analysis. The information on this page reflects the last day Aerpio Pharmaceuticals was actively traded. Get the latest Aerpio Pharmaceuticals detailed stock quotes, stock trade data, stock price info, and performance analysis, including Aerpio Stock investment advice, charts, stats and more.

Category: Contact NumberShow more

Should You Sell Aerpio Pharmaceuticals Inc (ARPO) Stock

3 hours ago Investorsobserver.com Show details

Aerpio Pharmaceuticals Inc has a Long-Term Technical rank of 85. This means that trading over the last 200 trading days has placed the company in the upper half of stocks with 15% of the market scoring higher. In the Biotechnology industry which is number 137 by this metric, ARPO ranks better than 94% of stocks. Important Dates for Investors in

Category: Contact NumberShow more

What is Aerpio Pharmaceuticals Valuation? ARPO Macroaxis

3 hours ago Macroaxis.com Show details

Aerpio Pharmaceuticals is number one stock in beta category among related companies. It is rated below average in price to earning category among related companies . . Comparative valuation analysis is a catch-all model that can be used if you cannot value Aerpio Pharmaceuticals by discounting back its dividends or cash flows.

Category: Contact NumberShow more

Aerpio Pharmaceuticals starts review of strategic

3 hours ago Spglobal.com Show details

Aerpio Pharmaceuticals Inc. has shuffled its management as it plans to explore strategic alternatives to maximize shareholder value. According to an Oct. 21 release, the Cincinnati-based company's clinical assets and cash resources totaled $48.2 million as of June 30. The board is exploring various options, including a possible acquisition

Category: Contact NumberShow more

Aerpio Pharmaceuticals Announces Results From TIME2b

8 hours ago Biospace.com Show details

CINCINNATI--(BUSINESS WIRE)-- Aerpio Pharmaceuticals, Inc. (Nasdaq:ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced top-line results from the Company’s TIME-2b study, a Phase 2b clinical trial designed to assess the efficacy and …

Category: Contact NumberShow more

Jobs with Aerpio Therapeutics BioSpace

1 hours ago Biospace.com Show details

Aerpio Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Tuesday, March 5, 2019. 2/26/2019. Aerpio Pharmaceuticals, Inc. announced that its fourth quarter and full year 2018 financial results will be released before the market opens on Tuesday, March 5, 2019.

Category: Contact NumberShow more

ARPO: Dividend Date & History for Aerpio Pharmaceuticals

9 hours ago Dividend.com Show details

Aerpio Pharmaceuticals Inc Dividend policy None Price as of: AUG 26, 05:00 PM EDT $33.0 -0.3 0% Dividend (Fwd) Consecutive Years of Dividend Increase is the number of years in a row in which there has been at least one payout increase and no payout decreases. Contact us About us FAQ DARS Ratings

Category: Contact NumberShow more

INVESTIGATION ALERT: Halper Sadeh LLP Investigates ONEM

5 hours ago Df.media Show details

Aerpio Pharmaceuticals, Inc. (NASDAQ: ARPO) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger with Aadi Bioscience, Inc. Under the merger, Aadi shareholders will receive newly issued shares of …

Category: Contact NumberShow more

SATTER MUNEER A SC 13D/A Filing Concerning AADI on 20211110

Just Now Whalewisdom.com Show details

021-11-12Aadi Bioscience, Inc. (f/k/a Aerpio Pharmaceuticals, Inc.) (Name of issuer) Common Stock, par value $0.0001 (Title of class of securities) 0032Q104 (CUSIP number) Muneer A. Satter . c/o Satter Management Co., L.P. 676 N. Michigan Avenue, Suite 4000, Chicago, IL 60611 (312) 448-5500 . COPY TO: Robert M. Hayward, P.C. Kirkland & Ellis LLP

Category: Contact NumberShow more

Aerpio Reports First Quarter 2021 Financial Results and

6 hours ago Apnews.com Show details

CINCINNATI, May 17, 2021 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2, today reported financial results for the first quarter ended March 31, 2021 and provided a business update.

Category: Contact NumberShow more

Amended Statement of Beneficial Ownership (sc 13d/a)

2 hours ago Ih.advfn.com Show details

(312) 448-5500Aadi Bioscience, Inc. (f/k/a Aerpio Pharmaceuticals, Inc.) (Name of issuer) Common Stock, par value $0.0001 (Title of class of securities) 0032Q104 (CUSIP number) Muneer A. Satter. c/o Satter Management Co., L.P. 676 N. Michigan Avenue, Suite 4000, Chicago, IL 60611 (312) 448-5500 . COPY TO: Robert M. Hayward, P.C. Kirkland & Ellis LLP. …

Category: Contact NumberShow more

Has Aerpio Pharmaceuticals (ARPO) Outpaced Other Medical

Just Now News.yahoo.com Show details

Download the Yahoo News app. Yahoo News. Search query

Category: Contact NumberShow more

Aerpio Reports Second Quarter 2021 Financial Results and

3 hours ago Ca.finance.yahoo.com Show details

Ended second quarter 2021 with $36.8 million in cash and cash equivalents On May 16, 2021, Aerpio entered into an agreement and plan of merger with Aadi Bioscience, Inc., which is subject to the approval of Aerpio shareholders and other customary closing conditions CINCINNATI, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. …

Category: Contact NumberShow more

Current Report Filing (8k) ADVFN

4 hours ago Ih.advfn.com Show details

On August 12, 2020, Aerpio Pharmaceuticals, Inc. announced its financial results for the quarter ended June 30, 2020. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K.. The information in this Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes …

Category: Contact NumberShow more

5 Best Penny Stocks to Buy Now Insider Monkey

5 hours ago Insidermonkey.com Show details

Number of Hedge Fund Holders: 12 . Aerpio Pharmaceuticals, Inc. (NASDAQ: ARPO) is ranked fifth on our list of 15 best penny stocks to buy now. The company operates from Ohio and makes and sells

Category: Contact NumberShow more

Aerpio Pharmaceuticals Raises $40 Million Business Wire

7 hours ago Businesswire.com Show details

Aerpio Pharmaceuticals successfully completes reverse merger and closes private placement of $40 Million. March 16, 2017 08:00 AM Eastern Daylight Time. CINCINNATI-- ( BUSINESS WIRE )--Aerpio

Category: Contact NumberShow more

Aerpio Pharmaceuticals Announces Results From TIME2b

2 hours ago Businesswire.com Show details

Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing first-in-class compounds that activate Tie2 to …

Category: Contact NumberShow more

Bill Daly, Chief Business Officer at Meissa Vaccines, Inc

6 hours ago Relationshipscience.com Show details

Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The firm's product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy.

Category: Contact NumberShow more

Aerie Pharmaceuticals Number of Employees 20122021 AERI

8 hours ago Macrotrends.net Show details

Aerie Pharmaceuticals number of employees from 2012 to 2021. Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis

Category: Contact NumberShow more

Orbimed Advisors Llc ownership in AADI / Aadi Biosciences

9 hours ago Fintel.io Show details

105 2018-08AERPIO PHARMACEUTICALS: COM: 00810B105 2018-08-14: 2018-06-30: 13F: AERPIO PHARMACEUTICALS: COM: 00810B105 Legend. Shares The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing. Value Contact us here.

Category: Contact NumberShow more

HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VEPTP …

3 hours ago Uspto.report Show details

020-08-27U.S. patent application number 16/851420 was filed with the patent office on 2020-08-27 for humanized monoclonal antibodies that target ve-ptp (hptp-beta). The applicant listed for this patent is AERPIO PHARMACEUTICALS, INC.. Invention is credited to Michael Allen FLYNN, Kevin PETERS.

Category: Contact NumberShow more

Aerpio Pharmaceuticals Inc (ARPO) Stock Price History

2 hours ago Wallmine.com Show details

Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing compounds that activate Tie2 for indications in which the Company believes that activation of Tie2 may have therapeutic potential. The Company's lead compound, razuprotafib (formerly AKB-9778), a first-in-class small molecule inhibitor of vascular endothelial protein …

Category: Contact NumberShow more

All Time Past 24 Hours Past Week Past month

Please leave your comments here:

Brand New Updated

Frequently Asked Questions

What is aerpio pharmaceuticals (Arpo) up to?

Aerpio Pharmaceuticals ( ARPO) is a biopharmaceutical company focused on developing compounds that activate Tie2. Tie2 is considered a key regulator of vascular stability, and ARPO “believes that activation of Tie2 may have therapeutic potential” for different indications.

What happened to aerpio stock after the upgrade?

Following the upgrade, ARPO stock soared 63.2% to close at $2.79. In relation to the merger, ARPO has entered subscription agreements for Private Investment in Public Equity (PIPE) financing to raise around $155 million. The closing of the PIPE financing will result in Aadi shareholders owning 29.6% of Aerpio’s shares.

Is Aadi Bioscience owned by aerpio?

In May, Aerpio announced the merger with Aadi Bioscience. The merger is expected to close in the second half of this year. The completion of the merger will result in ARPO becoming a wholly-owned subsidiary of Aadi.

How did aerpio's operating expenses increase in Q1?

Aerpio’s operating expenses increased 36.7% year-over-year to $5.6 million in Q1. The company had cash and cash equivalents of $39 million as of March 31. In May, Aerpio announced the merger with Aadi Bioscience. The merger is expected to close in the second half of this year.

Popular Brands

Amazon
Abbvie
Asml
Aia
Att
Apple
Amgen
Adobe
Aptar
Acc
Adidas
Aak